INTRODUCTION
The diagnosis of myocardial infarction (Ml) in The early cardiac isoenzyme serum marker assays were developed to confirm the diagnosis of MI.3 At the time when these markers were first introduced, Ml was considered to be an irreversible phenomenon, and hence diagnosis was mainly used for prognostic purposes; rapidity of test performance did not become a clinical concern until within the last ten years. Interventional treatment for Ml 'in evolution' and efforts to minimize in-patient resource use have changed laboratory testing priorities.
With the introduction of interventional therapy for Ml and the desire to minimize resource use by non-MI patients, the rapid availability of cardiac serum markers has become a reality in many clinical chemistry laboratories. While some laboratories still batch enzyme specimens for 'laboratory efficiency', many laboratories have adopted techniques for rapid automated or semiautomated analysis of single and serial specimens for in-patient chest pain decision-making. 4 The release of cellular markers from ischaemic tissue is time dependent. Enzymes and other markers must diffuse from infarcted tissue into cardiac veins or lymphatics and then return to the general circulation. Generally, the higher the concentration of the enzyme in the tissue and the more tissue that is infarcted, the higher the peak serum level. However, the interval between infarction and the onset of a measurable rise in CK-MB levels may also be related to adequate perfusion of the surrounding non-infarcted tissue, which enhances the return of marker-enriched blood and lymphatic fluid. This view is supported by observations that coronary reperfusion increases the rate of enzyme release from perfused tissue. 12 More recent CK-MB immunochemical technologies using antibodies to both the 'B' and the 'M' subunits measure the mass of CK-MB, confirmation of Ml required high threshold values in order to achieve maximum test specificity. Furthermore demonstrated that the test was only c. 42% sensitive at the time of patient presentation, but its sensitivity improved to c. 95% within 2 h of presentation and 100% by 8h following presentation.14 Gibler et at. noted that the CK-MB mass assay was c. 80% sensitive within 3 h of presentation and 100% sensitive within 12h of symptom onset. 8 Marin and Teichman noted that two ED CK-MB mass measurements taken 2 h apart were 94% sensitive for MI.9 Hence the sensitivity of the test for Ml can be satisfactorily estimated on the basis of the time interval between presentation (or symptom onset) and phlebotomy. Any application of CK-MB levels to clinical decision-making must take into consideration both the type of assay used (preferably a CK-MB mass assay rather than a CK-MB activity assay, and definitely not an electrophoretic assay) and the interval between symptom onset and specimen collection.
CK-MB levels are redundant with regard to ED ECGs However, the role of the CK-MB level in decisionmaking should be documented in the patient's ED record. For example, in a patient with atypical chest discomfort who presents 12 h after the onset of the discomfort, a negative test is a strong indicator that the patient does not have an Ml. The physician must then use other tools to decide whether the presentation warrants in-patient or out-patient treatment and further evaluation. The role of these other tools or findings in the decision-making process should also be documented in order to minimize retrospective assumptions by plaintiffs' attorneys.
J.R. Hedges Use of CK-MBs is not cost-effective
A formal cost-effectiveness anar sis of ED CK-MB use has yet to be performed. Early retrospective studies suggested that the observed 4 for the 265 patients released from the ED, the additional cost would be c. £26 500. Thus, on the basis of these crude assumptions, the additional expense of ED CK-MB levels appears to be more than balanced by savings made elsewhere.
CLINICAL APPLICATION OF CK-MB ORDERING
In clinical practice at my institution, ED CK-MB ordering is more selective than in the crude financial analysis outlined above. For those patients whose symptoms are not compatible with cardiac ischaemia (e.g. a young patient with sore chest wall associated with coughing and respiratory illness), ordering of CK-MB levels is discouraged. For individuals with discomfort that began more than 9-12 h before presentation, a single CK-MB level determination is generally sufficient. For the patient who presents within several hours of the onset of discomfort and clinically warrants admission, measurement of CK-MB levels is generally deferred until at least 6 h following symptom onset. Finally, patients with significant ST-segment or T-wave changes generally do not require ED CK-MB levels, although these data may be ordered for in-patient prognostic use rather than ED decision-making.
CONCLUSIONS
While an imperfect tool, CK-MB mass measurement in the ED may aid clinical decisionmaking. It must be looked upon as a supplement to clinical decision-making and not be used to supplant clinical thinking. Formal costeffectiveness analyses will require additional data on the impact of the test upon clinical decisionmaking and better estimates of the preventability of adverse outcomes by earlier Ml recognition. However, given the preliminary data, the marginal expense of the CK-MB mass assay does not appear to prohibit its selective application in the ED.
